Disease-modifying treatments are currently assessed in neurodegenerative diseases. Huntington's Disease represents a unique opportunity to design automatic sub-clinical markers, even in premanifest gene carriers. We investigated phonatory impairments as potential clinical markers and propose them for both diagnosis and gene carriers follow-up. We used two sets of features: Phonatory features and Modulation Power Spectrum Features. We found that phonation is not sufficient for the identification of sub-clinical disorders of premanifest gene carriers. According to our regression results, Phonatory features are suitable for the predictions of clinical performance in Huntington's Disease.
View on arXiv